[HTML][HTML] Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review
S Mahendiratta, S Bansal, P Sarma, H Kumar… - Biomedicine & …, 2021 - Elsevier
Abstract Background SARS-CoV-2, which majorly affects the lungs and respiratory tract is
thought due to dysregulation of the immune system which causes an immense imbalance of …
thought due to dysregulation of the immune system which causes an immense imbalance of …
Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial
ME Martínez-Muñoz, C Payares-Herrera… - Bone Marrow …, 2024 - nature.com
Mesenchymal stromal cells (MSC) have immunomodulatory and tissue-regenerative
properties and have shown promising results in acute respiratory distress syndrome (ARDS) …
properties and have shown promising results in acute respiratory distress syndrome (ARDS) …
[HTML][HTML] Adipose stem cells (ASCs) and stromal vascular fraction (SVF) as a potential therapy in combating (COVID-19)-disease
P Gentile, A Sterodimas - Aging and disease, 2020 - ncbi.nlm.nih.gov
A recent and interesting study reported improved respiratory activity after intravenous
administration of mesenchymal stem cells (MSCs) into patients affected by coronavirus …
administration of mesenchymal stem cells (MSCs) into patients affected by coronavirus …
[HTML][HTML] Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: preliminary results of a phase I/II clinical trial
C Grégoire, N Layios, B Lambermont… - Frontiers in …, 2022 - frontiersin.org
Background Treatment of acute respiratory distress syndrome (ARDS) associated with
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …
[HTML][HTML] Stem cell-based therapy for COVID-19 and ARDS: a systematic review
G Zanirati, L Provenzi, LL Libermann… - NPJ Regenerative …, 2021 - nature.com
Despite global efforts to establish effective interventions for coronavirus disease 2019
(COVID-19) and its major complications, such as acute respiratory distress syndrome …
(COVID-19) and its major complications, such as acute respiratory distress syndrome …
[HTML][HTML] Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review
BBS Armstrong, JCM Pedroso… - Clinics, 2023 - Elsevier
COVID-19 can converge with the pro-inflammatory immunoregulatory mechanisms of
chronic lung diseases. Given the disorders inherent to lung transplantation and the …
chronic lung diseases. Given the disorders inherent to lung transplantation and the …
[HTML][HTML] Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial
N Kaffash Farkhad, A Sedaghat, H Reihani… - Stem Cell Research & …, 2022 - Springer
Background Acute respiratory distress syndrome (ARDS) is the devastating complication of
the new COVID-19 pandemic, directly correlated with releasing large amounts of …
the new COVID-19 pandemic, directly correlated with releasing large amounts of …
[HTML][HTML] Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia
AK Shetty - Aging and disease, 2020 - ncbi.nlm.nih.gov
A new study published by the journal Aging & Disease reported that intravenous
administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with …
administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with …
[HTML][HTML] Mesenchymal stem cells in the treatment of new coronavirus pandemic: a novel promising therapeutic approach
S Razi, Z Molavi, SA Mirmotalebisohi… - Advanced …, 2022 - ncbi.nlm.nih.gov
After severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome
(MERS) outbreaks, coronavirus disease 2019 (COVID-19) is the third coronavirus epidemic …
(MERS) outbreaks, coronavirus disease 2019 (COVID-19) is the third coronavirus epidemic …
Mesenchymal stem cell therapy for COVID-19 infection
SMM Alavi-Dana, Y Gholami, M Meghdadi… - …, 2023 - Springer
COVID-19 emerged in December 2019 in Wuhan, China, spread worldwide rapidly, and
caused millions of deaths in a short time. Many preclinical and clinical studies were …
caused millions of deaths in a short time. Many preclinical and clinical studies were …